The 2013 Tour de France had no positive anti-doping test results, it was announced today at a media Open Day in Aigle, Switzerland, by the Cycling Anti-Doping Foundation (CADF) Director Francesca Rossi.
The CADF took 622 blood and urine samples during the 100th edition of the Tour (versus a total of 566 samples in 2012). Working closely with the French Anti-Doping Agency (AFLD), the CADF took 202 pre-competition samples and a further 419 samples during the race.
Reinforcing the strategy of targeted testing, 198 of the samples taken during the race were for the purposes of the biological passport (versus 149 samples in 2012).
“This target testing strategy has been hugely facilitated by the excellent on-site cooperation between CADF and AFLD during the race,” said Dr Rossi.
The samples were analysed by the WADA-accredited laboratories of Châtenay-Malabry (France), Lausanne (Switzerland) and Cologne (Germany). The UCI and AFLD have also agreed to keep the samples taken for possible retrospective testing in the future.